Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04454463 · ClinicalTrials.gov registry record
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
A clinical trial, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- 1,649
- Enrollment target
NCT04454463: Completed study, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT04454463 is a clinical trial that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 1,649 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04454463 has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- 1,649 participants
- Enrollment target
Study Summary
The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients suspected or known to have NAFLD or NASH-related cirrhosis. To elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular its more severe form of NASH and its complications.
Primary Outcome
ALT measure in IU/L (higher ALT indicates worse outcomes)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,649 participants |
| Start Date | 2020-11-13 |
| Est. Completion | 2025-07-09 |
What the finished NCT04454463 record still lists
NCT04454463 is an observational study that tracks outcomes without assigning an intervention. Its 1,649 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04454463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04454463 about?
NCT04454463 is a clinical study titled "Nonalcoholic Fatty Liver Disease (NAFLD) Database 3". The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients suspected or known to have NAFLD or NASH-related cirrhosis. To elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnos...
What is the current status of trial NCT04454463?
This trial is currently completed. The enrollment target is 1,649 participants. The study started on 2020-11-13. Estimated completion is 2025-07-09.
Who is sponsoring clinical trial NCT04454463?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- NCT07046260 · 1,650 participants
Prospective Study to Assess a Diagnostic Aid for Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI